Ziprasidone

Half-Life (t½)
PO: 7h · IM: 3h
Formula
C21H21ClN4OS
Molecular Weight
412.94 g/mol
PubChem CID
60854
Aliases
Geodon, Zeldox

Pharmacological Mechanism

Atypical antipsychotic; potent D2 / 5-HT2A antagonist. Notable for a clinically significant food effect (oral absorption ~doubles with a ≥500 kcal meal) and QT prolongation (hERG block). Oral + IM (acute agitation).

Half-Life & Elimination Curve (PO: 7h · IM: 3h)

100%50%25%12.5%0%0h0×t½7h1×t½14h2×t½21h3×t½28h4×t½35h5×t½0×t½ (0h): 100% remaining (~0.252 mg/L)1×t½ (7h): 50% remaining (~0.126 mg/L)2×t½ (14h): 25% remaining (~63.1 µg/L)3×t½ (21h): 12.5% remaining (~31.6 µg/L)4×t½ (28h): 6.3% remaining (~15.8 µg/L)5×t½ (35h): 3.1% remaining (~7.89 µg/L)
Plasma (PO)t½ Decay (7h)Effect Site (ke0)
  • 0×t½0h100% (0.252 mg/L)
  • 1×t½7h50% (0.126 mg/L)
  • 2×t½14h25% (63.1 µg/L)
  • 3×t½21h12.5% (31.6 µg/L)
  • 4×t½28h6.3% (15.8 µg/L)
  • 5×t½35h3.1% (7.89 µg/L)
Elimination t½7h (PO)
Rate Constant (ke)0.099 h⁻¹
Time to Peak (Tmax)6h
Est. Peak (Cmax)0.252 mg/L
Clearance (CL)10.4 L/h
97% Washout (5×t½)35h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Target Organ Systems

Chemical Structure & Identifiers

References